与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 8-K Current report, items 5.03, 7.01, 8.01, and 9.01 Accession Number: 0001104659-23-004326 Act: 34 Size: 780 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001104659-23-003629 Act: 34 Size: 375 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000919 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, item 8.01 Accession Number: 0001104659-23-002936 Act: 34 Size: 199 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000764 Size: 6 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000765 Size: 6 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-000766 Size: 6 KB 网页链接
$井寺制药(IDRA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-22-129602 Act: 33 Size: 154 KB 网页链接
$井寺制药(IDRA)$ 8-K/A [Amend] Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-125903 Act: 34 Size: 228 KB 网页链接
$井寺制药(IDRA)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-22-125528 Act: 34 Size: 5 MB 网页链接